JP2021526860A5 - - Google Patents
Info
- Publication number
- JP2021526860A5 JP2021526860A5 JP2021518054A JP2021518054A JP2021526860A5 JP 2021526860 A5 JP2021526860 A5 JP 2021526860A5 JP 2021518054 A JP2021518054 A JP 2021518054A JP 2021518054 A JP2021518054 A JP 2021518054A JP 2021526860 A5 JP2021526860 A5 JP 2021526860A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- group
- composition according
- grna
- hla
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682276P | 2018-06-08 | 2018-06-08 | |
| US62/682,276 | 2018-06-08 | ||
| PCT/US2019/036050 WO2019236998A1 (en) | 2018-06-08 | 2019-06-07 | Compositions and methods for the modulation of adaptive immunity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021526860A JP2021526860A (ja) | 2021-10-11 |
| JPWO2019236998A5 JPWO2019236998A5 (https=) | 2022-06-15 |
| JP2021526860A5 true JP2021526860A5 (https=) | 2022-06-15 |
Family
ID=68769461
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021518054A Pending JP2021526860A (ja) | 2018-06-08 | 2019-06-07 | 適応免疫をモジュレートするための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190382759A1 (https=) |
| EP (1) | EP3801641A4 (https=) |
| JP (1) | JP2021526860A (https=) |
| KR (1) | KR20210060429A (https=) |
| CN (1) | CN113286619A (https=) |
| AU (1) | AU2019281006A1 (https=) |
| CA (1) | CA3102783A1 (https=) |
| SG (1) | SG11202012015YA (https=) |
| WO (1) | WO2019236998A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9499805B2 (en) | 2010-06-18 | 2016-11-22 | The University Of North Carolina At Chapel Hill | Methods and compositions for synthetic RNA endonucleases |
| US20190284553A1 (en) | 2018-03-15 | 2019-09-19 | KSQ Therapeutics, Inc. | Gene-regulating compositions and methods for improved immunotherapy |
| JP2021526858A (ja) | 2018-06-08 | 2021-10-11 | ロックアネイビオ， インコーポレイテッド | Ｒｎａ標的化融合タンパク質組成物および使用方法 |
| AU2020208346B2 (en) | 2019-01-14 | 2026-01-29 | University Of Rochester | Targeted nuclear RNA cleavage and polyadenylation with CRISPR-cas |
| WO2021011504A1 (en) * | 2019-07-12 | 2021-01-21 | Duke University | Nanoparticle systems for targeted delivery of crispr/cas13 and methods of using same |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| AU2021392032A1 (en) | 2020-12-03 | 2023-06-22 | Century Therapeutics, Inc. | Genetically engineered cells and uses thereof |
| CN113136376B (zh) * | 2021-05-26 | 2022-10-21 | 武汉大学 | 一种Cas12a变体及其在基因编辑中的应用 |
| WO2023150131A1 (en) * | 2022-02-01 | 2023-08-10 | The Regents Of The University Of California | Method of regulating alternative polyadenylation in rna |
| CN114848808B (zh) * | 2022-03-24 | 2023-04-25 | 四川大学 | 基于阳离子脂多肽及细胞因子的免疫增强剂及制法、应用 |
| CN114720699A (zh) * | 2022-04-22 | 2022-07-08 | 浙江大学 | 一种结直肠癌早期预警血清指标及其检测方法和应用 |
| CN116949011A (zh) * | 2022-04-26 | 2023-10-27 | 中国科学院动物研究所 | 经分离的Cas13蛋白、基于它的基因编辑系统及其用途 |
| CN115068632A (zh) * | 2022-06-22 | 2022-09-20 | 华中科技大学同济医学院附属同济医院 | Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法 |
| WO2024264035A2 (en) * | 2023-06-22 | 2024-12-26 | The General Hospital Corporation | Compositions and methods of generating endogenous tdr molecules |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019500899A (ja) * | 2015-11-23 | 2019-01-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＣＲＩＳＰＲ／Ｃａｓ９の核送達を通じた細胞ＲＮＡの追跡と操作 |
| EA201891338A1 (ru) * | 2015-12-04 | 2018-12-28 | Новартис Аг | Композиции и способы для иммуноонкологии |
| US12180499B2 (en) * | 2016-10-31 | 2024-12-31 | University Of Florida Research Foundation, Inc. | Compositions and methods for impeding transcription of expanded microsatellite repeats |
| AU2018234825B2 (en) * | 2017-03-15 | 2020-12-17 | Massachusetts Institute Of Technology | Novel CAS13B orthologues CRISPR enzymes and systems |
| US11168322B2 (en) * | 2017-06-30 | 2021-11-09 | Arbor Biotechnologies, Inc. | CRISPR RNA targeting enzymes and systems and uses thereof |
-
2019
- 2019-06-07 US US16/434,787 patent/US20190382759A1/en not_active Abandoned
- 2019-06-07 CA CA3102783A patent/CA3102783A1/en active Pending
- 2019-06-07 AU AU2019281006A patent/AU2019281006A1/en not_active Abandoned
- 2019-06-07 CN CN201980051039.7A patent/CN113286619A/zh active Pending
- 2019-06-07 KR KR1020217000507A patent/KR20210060429A/ko not_active Ceased
- 2019-06-07 JP JP2021518054A patent/JP2021526860A/ja active Pending
- 2019-06-07 SG SG11202012015YA patent/SG11202012015YA/en unknown
- 2019-06-07 EP EP19814000.6A patent/EP3801641A4/en active Pending
- 2019-06-07 WO PCT/US2019/036050 patent/WO2019236998A1/en not_active Ceased
-
2023
- 2023-11-09 US US18/505,709 patent/US20240344060A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021526860A5 (https=) | ||
| US12280111B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| Bukczynski et al. | Costimulatory ligand 4-1BBL (CD137L) as an efficient adjuvant for human antiviral cytotoxic T cell responses | |
| JP2021526858A5 (https=) | ||
| EP3920942A2 (en) | Combination gene targets for improved immunotherapy | |
| JP2019500043A5 (https=) | ||
| CN112040987A (zh) | 用于改进的免疫疗法的基因调控组合物和方法 | |
| JP2021518160A5 (https=) | ||
| AU2021216418A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| US11332713B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| AU2020215725B2 (en) | Gene-regulating compositions and methods for improved immunotherapy | |
| Chakravarti et al. | Inducible gene switches with memory in human T cells for cellular immunotherapy | |
| JPWO2019236998A5 (https=) | ||
| Middelburg et al. | The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent | |
| Haeryfar et al. | Terminal deoxynucleotidyl transferase establishes and broadens antiviral CD8+ T cell immunodominance hierarchies | |
| WO2022012531A1 (zh) | 一种经修饰的免疫细胞的制备方法 | |
| Ploquin et al. | B cells and TCR avidity determine distinct functions of CD4+ T cells in retroviral infection | |
| Yang et al. | A simplified method for the clinical-scale generation of central memory-like CD8+ T cells after transduction with lentiviral vectors encoding antitumor antigen T-cell receptors | |
| US20190309260A1 (en) | Artificial antigen-presenting cell prepared from hla-null cell line by using multiplex crispr-cas9 system and use thereof | |
| US20250034558A1 (en) | Compositions and methods for targeting, editing or modifying human genes | |
| Ling et al. | Microparticles as immune regulators in infectious disease–an opinion | |
| Corrigan et al. | In vivo reprogramming of cytotoxic effector CD8+ T cells via fractalkine-conjugated mRNA-LNP | |
| Chen et al. | In vivo analysis of adenovirus-specific cytotoxic T lymphocyte response in mice deficient in CD28, fas ligand, and perforin | |
| CN117940465A (zh) | 经修饰的细胞、其制备方法及应用 | |
| EP1930438A1 (en) | Transcription factor for killer cell activation, differentiation and uses thereof |